

Zhong Yuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5183567/publications.pdf>

Version: 2024-02-01

17
papers

682
citations

1039406

9
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

1035
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor. <i>Circulation</i> , 2018, 137, 1450-1459.	1.6	194
2	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2585-2597.	2.2	164
3	Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose cotransporter-2 inhibitors in the USA: A retrospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 582-589.	2.2	108
4	Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2017, 128, 83-90.	1.1	53
5	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose cotransporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1620-1628.	0.9	36
6	Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. <i>Current Medical Research and Opinion</i> , 2014, 30, 1733-1741.	0.9	27
7	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. <i>Chest</i> , 2016, 150, 1059-1068.	0.4	24
8	Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00096.	1.0	14
9	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
10	Benefit-Risk Evaluation and Decision Making: Some Practical Insights. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 425-433.	0.8	9
11	Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2015, 31, 1257-1266.	0.9	9
12	Benefit-risk assessment: to quantify or not to quantify, that is the question. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 653-656.	0.9	8
13	Risk Prediction for Ischemic Stroke and Transient Ischemic Attack in Patients Without Atrial Fibrillation: A Retrospective Cohort Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1721-1731.	0.7	8
14	Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA. <i>Drug Safety</i> , 2021, 44, 479-497.	1.4	7
15	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. <i>Wellcome Open Research</i> , 2020, 5, 253.	0.9	4
16	Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. <i>Clinical Therapeutics</i> , 2021, 43, 2074-2087.	1.1	4
17	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1117-1124.	0.9	3